About Insmed
Insmed is a company based in Bridgewater (United States) founded in 1999. The company has 1,270 employees as of December 31, 2024. Insmed has completed 2 acquisitions, including Adrestia and Transave. Insmed offers products and services including ARIKAYCE, Brensocatib, and TPIP. Insmed operates in a competitive market with competitors including Affinivax, Eligo Bioscience, Aridis Pharma, Basilea and MaaT Pharma, among others.
- Headquarter Bridgewater, United States
- Employees 1270 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Insmed Incorporated
-
Annual Revenue
$363.71 M (USD)19.17as on Dec 31, 2024
-
Net Profit
-$913.77 M (USD)-21.91as on Dec 31, 2024
-
EBITDA
-$775.56 M (USD)-15.69as on Dec 31, 2024
-
Latest Funding Round
$450 M (USD), Post-IPO
Jan 01, 2018
- Investors
-
Employee Count
1270
as on Dec 31, 2024
-
Investments & Acquisitions
Adrestia
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Insmed
Insmed is a publicly listed company on the NASDAQ with ticker symbol INSM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Insmed
Insmed offers a comprehensive portfolio of products and services, including ARIKAYCE, Brensocatib, and TPIP.
Treatment for nontuberculous mycobacterial lung disease via inhalation.
Inhibitor targeting inflammatory diseases in clinical development.
Early-stage compound for potential disease therapies.
People of Insmed
Unlock access to complete
Leadership Team
172 people
Software Development Team
54 people
Operations Team
36 people
Senior Team
34 people
Sales and Marketing
30 people
Product Management Team
21 people
Legal and Compliance
17 people
Finance and Accounting
15 people
Unlock access to complete
Funding Insights of Insmed
Investors in Insmed
Insmed has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include United States Department of Agriculture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Leadership is provided on agriculture, food, and rural development matters.
|
Locked | Locked | Locked |
Investor details for Insmed
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Insmed
Insmed has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Adrestia and Transave.
Investment portfolio details for Insmed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Pharmaceutical drugs for multiple therapeutic areas are manufactured.
|
Locked | Locked | 2018 | Locked | |
|
Developer of inhaled pharmaceuticals for the site-specific treatment of serious lung infections
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for Insmed
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Insmed
Detailed financials for Insmed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Insmed Comparisons
Peer comparison for Insmed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Insmed
Insmed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Affinivax, Eligo Bioscience, Aridis Pharma, Basilea and MaaT Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| Locked | Locked | Locked |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| Locked | Locked | Locked |
Provider of human monoclonal antibodies against infectious diseases
|
|
| Locked | Locked | Locked |
Antibiotics, antifungals, and oncology drugs are developed for disease treatment.
|
|
| Locked | Locked | Locked |
Microbiome therapies are developed for treating intestinal dysbiosis diseases.
|
Detailed competitors of Insmed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Insmed
Complete news archive for Insmed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Insmed
Insmed was founded in 1999 and raised its 1st funding round 11 years after it was founded.
Insmed is headquartered in Bridgewater, United States. It is registered at Bridgewater, New Jersey, United States.
Will Lewis is the current CEO of Insmed.
As of Dec 31, 2024, the latest employee count at Insmed is 1,270.
Annual revenue of Insmed is $363.71M as on Dec 31, 2024.
Developer of small molecule inhibitors for rare lung diseases. Its lead candidate is Arikayce (liposomal amikacin for inhalation), a ribosomal 30S subunit inhibitor for nontuberculous mycobacteria (NTM) lung disease. It also has an earlier-stage clinical pipeline which includes INS1009, a nebulized prodrug formulation of treprostinil that claims to have potential in rare pulmonary disorders such as pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF) sarcoidosis, and severe refractory asthma.
Insmed's top competitors include Aridis Pharma, MaaT Pharma and Basilea.
Insmed offers ARIKAYCE, Brensocatib, and TPIP.
Yes, Insmed is publicly traded on NASDAQ under the ticker symbol INSM.
Insmed has 1 investor. Key investors include United States Department of Agriculture.
The ticker symbol of Insmed is INSM on NASDAQ.